Treating Painful Diabetic Peripheral Neuropathy: An Update.
Abstract
Painful diabetic peripheral neuropathy occurs in approximately 25% of patients with diabetes mellitus who are treated in the office setting and significantly affects quality of life. It typically causes burning pain, paresthesias, and numbness in a stocking-glove pattern that progresses proximally from the feet and hands. Clinicians should carefully consider the patient's goals and functional status and potential adverse effects of medication when choosing a treatment for painful diabetic peripheral neuropathy. Pregabalin and duloxetine are the only medications approved by the U.S. Food and Drug A...
Source: American Family Physician - July 31, 2016 Category: Primary Care Authors: Snyder MJ, Gibbs LM, Lindsay TJ Tags: Am Fam Physician Source Type: research
Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder
Journal of Child and Adolescent Psychopharmacology , Vol. 0, No. 0. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - July 17, 2016 Category: Pediatrics Authors: Robert L. FindlingJames GroarkKaren A. TourianSara A. RamakerDeborah ChilesLingfeng YangAlice I. Nichols Source Type: research
Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis
Introduction
Many antidepressants are indicated for the treatment of major depression. Two network meta-analyses have provided the most comprehensive assessments to date, accounting for both direct and indirect comparisons; however, these reported conflicting interpretation of results. Here, we present a protocol for a systematic review and network meta-analysis aimed at updating the evidence base and comparing all second-generation as well as selected first-generation antidepressants in terms of efficacy and acceptability in the acute treatment of major depression.
Methods and analysis
We will include all randomised cont...
Source: BMJ Open - July 7, 2016 Category: Journals (General) Authors: Furukawa, T. A., Salanti, G., Atkinson, L. Z., Leucht, S., Ruhe, H. G., Turner, E. H., Chaimani, A., Ogawa, Y., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Suganuma, A., Watanabe, N., Stockton, S., Geddes, J. R., Cipriani, A. Tags: Open access, Mental health, Pharmacology and therapeutics, Research methods Protocol Source Type: research
The Effects of Desvenlafaxine on Neurocognitive and Work Functioning in Employed Outpatients with Major Depressive Disorder
We examined the association between neurocognitive and work functioning in employed patients with MDD. (Source: Journal of Affective Disorders)
Source: Journal of Affective Disorders - May 30, 2016 Category: Neurology Authors: Raymond W. Lam, Grant L. Iverson, Vanessa C. Evans, Lakshmi N. Yatham, Kurtis Stewart, Edwin M. Tam, Auby Axler, Cindy Woo Tags: Research paper Source Type: research
A Multi-layered Particulate System for Desvenlafaxine Succinate Oral Customized Release.
Abstract
A prolonged release Desvenlafaxine succinate (DSV) multilayered system was prepared by the ionotropic gelation using sodium alginate (SA) and calcium chloride as a cross-linker. Such prolonged release could decrease the rapid DSV absorption after oral administration and reduce its exaggerated side effects. DSV was incorporated simultaneously during the gelation stage and the formed beads were evaluated for shape and particle size. Thirteen formulation variables including pH, DSV: polymer ratio, cross-linker concentration and curing time were optimized for optimal drug entrapment. The optimized for...
Source: Current Drug Delivery - May 22, 2016 Category: Drugs & Pharmacology Authors: Elgindy N, Elnobya A, El-Gowelli HM, Samya W Tags: Curr Drug Deliv Source Type: research
Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain
Conclusions In patients who have not responded to a first-line serotonin-specific reuptake inhibitor therapy, desvenlafaxine-50mg was clinically similar in effectiveness, but a less costly option, compared with a weighted average of duloxetine and venlafaxine for the second-line treatment of major depressive disorder patients from a payer (National Health System) perspective in Spain. (Source: Revista de Psiquiatria y Salud Mental)
Source: Revista de Psiquiatria y Salud Mental - May 11, 2016 Category: Psychiatry Source Type: research
The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial
The objective of this substudy was to examine the effect of desvenlafaxine 50 mg/day compared with placebo on cognitive function in employed outpatients with major depressive disorder. A total of 11/55 (20%) study sites in a 12-week, randomized, double-blind, placebo-controlled trial administered cognitive assessments in memory, attention, and executive functioning domains using the cognitive drug research system. Changes from baseline were subjected to analysis of covariance with baseline levels as covariates, using last observation carried forward data. A significant improvement with desvenlafaxine 50 mg/day (n=52) compa...
Source: Journal of Psychopharmacology - May 9, 2016 Category: Psychiatry Authors: Reddy, S., Fayyad, R., Edgar, C. J., Guico-Pabia, C. J., Wesnes, K. Tags: Original Papers Source Type: research
Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome
This article is protected by copyright. All rights reserved (Source: Clinical Pharmacology in Drug Development)
Source: Clinical Pharmacology in Drug Development - May 2, 2016 Category: Drugs & Pharmacology Authors: Rob Allen, Uma Sharma, Suna Barlas Tags: Original Manuscript Source Type: research
Persistence And Concomitant Drug Use On Branded Desvenlafaxine Compared With Other Antidepressants In Patients With Major Depressive Disorder
To compare medication persistence and concomitant MDD drug use in patients prescribed i) branded desvenlafaxine, ii) other branded selective serotonin re-uptake inhibitors (SSRIs) and selective serotonin-norepinephrine re-uptake inhibitors (SNRIs), and iii) generic SSRIs/SNRIs (escitalopram, venlafaxine, citalopram, fluvoxamine, sertraline, fluoxetine and paroxetine). (Source: Value in Health)
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Shelbaya, C Deshpande, E Pappadopulos, J Alvir, V Chirikov, JM Stephens Source Type: research
An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder
The chronic course of major depressive disorder (MDD) often impedes the ability of patients to achieve full remission. Return of full functioning is a critical goal of antidepressant pharmacotherapy as the presence of residual depressive symptoms is associated with an increased risk of relapse. Treatment guidelines recommend selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, or atypical antidepressants as first-line treatment for moderate to severe MDD. Desvenlafaxine, administered as desvenlafaxine succinate, is an serotonin–norepinephrine reuptake inhibitor approved for the treatme...
Source: International Clinical Psychopharmacology - March 31, 2016 Category: Psychiatry Tags: Original Articles Source Type: research
A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder
PharmacopsychiatryDOI: 10.1055/s-0042-103968No studies to date have evaluated SLC6A2 and SLC6A4 genetic polymorphisms influencing antidepressant response to desvenlafaxine. We conducted an 8-week, open-label, prospective pilot study in 35 patients with major depressive disorder to assess the effects of genetic variations in SLC6A2 and SLC6A4 on both efficacy and side effect profile of desvenlafaxine. Results revealed that homozygotes for the SLC6A4 HTTLPR S allele showed a 33% HDRS reduction compared to a 58% reduction for L allele carriers (p=0.037). No results survived adjustments for covariates or multiple comparisons. ...
Source: Pharmacopsychiatry - March 28, 2016 Category: Psychiatry Authors: Ng, C. H.Bousman, C.Smith, D. J.Dowling, N.Byron, K.King, J.Sarris, J. Tags: Letter to the Editor Source Type: research
NMR-based metabonomic analysis of normal rat urine and faeces in response to (±)-venlafaxine treatment
Publication date: 10 May 2016 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 123 Author(s): José I. Serrano-Contreras, Isabel García-Pérez, María E. Meléndez-Camargo, Luis G. Zepeda-Vallejo (±)-Venlafaxine, a bicyclic antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class, is prescribed for the treatment of depression and anxiety disorders. As is the case with other antidepressants, its precise mechanisms of action are still unknown. Pharmacometabonomic approaches allow for the detection of diverse metabolites, unlike classic methods for analysing drug interaction...
Source: Journal of Pharmaceutical and Biomedical Analysis - March 5, 2016 Category: Drugs & Pharmacology Source Type: research
Combined use of desvenlafaxine and electroconvulsive therapy.
PMID: 27099215 [PubMed - in process] (Source: Actas Espanolas de Psiquiatria)
Source: Actas Espanolas de Psiquiatria - February 29, 2016 Category: Psychiatry Authors: Martín-Larrégola M, Gómez-Arnau J, Rodríguez-Salgado B, Dolengevich-Segal H Tags: Actas Esp Psiquiatr Source Type: research
Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
Conclusions Desvenlafaxine 50 and 100 mg/d significantly improved depression compared with placebo in patients with and without metabolic syndrome, and in patients with baseline TSH above median and at or below median levels.
PMID: 26709542 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - February 18, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
NMR-based pharmacometabonomic analysis of normal rat urine and faeces in response to (±)-venlafaxine treatment
Publication date: 10 May 2016 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 123 Author(s): José I. Serrano-Contreras, Isabel García-Pérez, María E. Meléndez-Camargo, Luis G. Zepeda-Vallejo (±)-Venlafaxine, a bicyclic antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class, is prescribed for the treatment of depression and anxiety disorders. As is the case with other antidepressants, its precise mechanisms of action are still unknown. Pharmacometabonomic approaches allow for the detection of diverse metabolites, unlike classic methods for analysing drug interaction...
Source: Journal of Pharmaceutical and Biomedical Analysis - February 17, 2016 Category: Drugs & Pharmacology Source Type: research
